Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study.

Clin Ophthalmol · 2020 · PMC7605973 · PMID 33154619

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Monthly treatment showed a nonsignificant trend towards better BCVA and reduction in CMT compared to PRN treatment whereas treatment on a PRN protocol required an average of three less injections compared to monthly.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.